For patients living with major depressive disorder (MDD) or traumatic brain injury (TBI), overlapping symptoms like sleep disturbances, neuropathic pain, and mood disorders can feel unmanageable. Traditional treatments often fall short, but repetitive Transcranial Magnetic Stimulation (rTMS)—a noninvasive neurostimulation therapy—has emerged as a game-changer. Recent research across four key studies reveals rTMS’s multifaceted benefits: from improving sleep in depression to relieving pain in TBI. This article synthesizes findings from these pivotal studies, offering clarity on how rTMS works, who it helps, and why it’s reshaping mental health and neurorehabilitation care.

rTMS and Depression: Sleep Improvement Independent of Mood

A core question in depression treatment is whether sleep improvements stem from reduced mood symptoms or direct therapeutic effects. A 2022 study by Collins et al. (2022) sought to answer this by analyzing 21 MDD patients who received 6 weeks of 10 Hz rTMS targeting the left dorsolateral prefrontal cortex (DLPFC). Using the Pittsburgh Sleep Quality Index (PSQI) and a modified Patient Health Questionnaire-9 (PHQ-9, excluding sleep items), the team found that sleep quality (PSQI scores) and depressive symptoms both improved significantly post-treatment—but the changes were uncorrelated (Collins et al., 2022). Even after adjusting for age, sex, and sedative use, rTMS exerted independent effects on mood and sleep (Collins et al., 2022). This means rTMS doesn’t just fix sleep by easing depression—it directly targets sleep disturbances, offering hope for patients for whom sleep issues persist despite mood improvements.

Subgroup analysis added nuance: sleep quality improved most in male patients, those under 50, and those with mild-to-moderate depression (Collins et al., 2022). Notably, even patients whose depression didn’t respond to rTMS experienced better sleep, highlighting the therapy’s unique value for treatment-resistant sleep issues in MDD (Collins et al., 2022).

Baseline Insomnia Doesn’t Predict rTMS Efficacy—But Sleep Meds May Help

For depression patients with insomnia, a 2024 study by Kweon et al. (2024) debunked a key myth: baseline sleep quality doesn’t determine how well rTMS works for depression. Analyzing 975 patients across two clinics, the team found that while rTMS significantly improved both insomnia (33% reduction in scores) and depressive symptoms (40.7% reduction in QIDS scores), baseline insomnia severity didn’t predict treatment response (Kweon et al., 2024). However, a critical finding emerged: patients with severe baseline insomnia who used sleep medications had better post-treatment depression outcomes than those who didn’t—even though their final insomnia scores were similar (Kweon et al., 2024). This suggests combining rTMS with sleep meds may optimize antidepressant effects, possibly by restoring synaptic plasticity disrupted by chronic insomnia (Kweon et al., 2024).

The study also noted that sleep improvements correlated with mood gains (r=0.318, p<.001), but baseline sleep quality didn’t hinder rTMS’s efficacy—good news for patients worried their insomnia will limit treatment success (Kweon et al., 2024).

Sleep Improvement Predicts Depression Remission in TBI Veterans

TBI and depression often coexist, with sleep dysfunction worsening both conditions. A 2024 study by Norred et al. (2024) focused on 854 U.S. veterans with TBI, finding that 94.3% reported baseline sleep disturbances—and improvements in sleep during rTMS strongly predicted depression remission. Veterans who saw sleep gains at week 1 (27.84% remission rate), week 3 (29.32%), or week 6 (30.99%) were far more likely to recover from depression than those who didn’t (18.15%, 14.52%, and 9.94% remission rates, respectively) (Norred et al., 2024). Additionally, sleep improvements correlated with greater reductions in PHQ-8 scores (modified to exclude sleep items), with the largest mean improvement (4.825 points) seen in patients who improved sleep by week 6 (Norred et al., 2024).

This study underscores sleep as a “predictive marker” for rTMS success in TBI-related depression. For clinicians, monitoring sleep during treatment can help identify which patients may need adjusted protocols (Norred et al., 2024).

rTMS Relieves Pain and Postconcussion Symptoms in TBI

Beyond mood and sleep, rTMS addresses key TBI complications: neuropathic pain and postconcussion syndrome (PCS). A 2022 systematic review and meta-analysis by Li et al. (2022) analyzed 12 RCTs involving 276 TBI patients, finding that rTMS significantly reduced neuropathic pain (MD = -1.00, 95% CI: -1.76 to -0.25, P = 0.009) with the most pronounced relief during and immediately after treatment (Li et al., 2022). The therapy also improved PCS symptoms as measured by the Rivermead Post-Concussion Symptoms Questionnaire-13 (RPQ-13), with a pooled mean reduction of 5.87 points (P = 0.02) (Li et al., 2022).

Notably, rTMS was safe—no major adverse events were reported—and mild side effects (headache, scalp discomfort) were temporary (Li et al., 2022). While effects on depression and cognition were limited overall, subgroup analysis showed 1 Hz rTMS targeting the right DLPFC improved depression (MD = -6.52, P = 0.01), highlighting the importance of personalized protocols (Li et al., 2022).

Key Takeaways for Patients and Clinicians

Across four studies, rTMS emerges as a versatile, safe therapy with clear benefits:

1. Depression and sleep: rTMS improves sleep independently of mood (Collins et al., 2022), making it ideal for patients with treatment-resistant sleep issues.
2. Insomnia and rTMS optimization: Baseline insomnia doesn’t limit rTMS efficacy, but sleep meds may boost antidepressant effects (Kweon et al., 2024).
3. TBI and depression: Sleep improvement during rTMS predicts depression remission (Norred et al., 2024), offering a actionable monitoring tool.
4. TBI pain and PCS: rTMS reliably relieves neuropathic pain and postconcussion symptoms (Li et al., 2022), filling a critical gap in neurorehabilitation.

For patients, rTMS offers a non-pharmacological option with minimal side effects—no dependency, no daytime drowsiness. For clinicians, the research highlights the need for personalized targeting (e.g., right DLPFC for TBI-related depression) and sleep monitoring to guide care.

References

1. Collins, A. R., Cheung, J., Croarkin, P. E., Kolla, B. P., & Kung, S. (2022). Effects of transcranial magnetic stimulation on sleep quality and mood in patients with major depressive disorder. Journal of Clinical Sleep Medicine, 18(5), 1297–1305. https://pmc.ncbi.nlm.nih.gov/articles/PMC9059593/
2. Kweon, J., Fukuda, A. M., Gobin, A. P., Haq, L., Carpenter, L. L., & Brown, J. C. (2024). Effect of sleep quality on repetitive transcranial magnetic stimulation outcomes in depression. Frontiers in Psychiatry, 15, 1458696. https://pmc.ncbi.nlm.nih.gov/articles/PMC11456523/
3. Norred, M. A., Zuschlag, Z. D., Madore, M. R., Philip, N. S., & Kozel, F. A. (2024). Sleep as a predictor of improved response to transcranial magnetic stimulation for depression (SPIRiTeD). Journal of Affective Disorders, 362, 9–13. https://pmc.ncbi.nlm.nih.gov/articles/PMC11921995/#S1
4. Li, X., Lu, T., Yu, H., Shen, J., Chen, Z., Yang, X., Huang, Z., Yang, Y., Feng, Y., Zhou, X., & Du, Q. (2022). Repetitive transcranial magnetic stimulation for neuropathic pain and neuropsychiatric symptoms in traumatic brain injury: A systematic review and meta-analysis. Neural Plasticity, 2022, 2036736. https://pmc.ncbi.nlm.nih.gov/articles/PMC9357260/